Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus.
Dipeptidyl peptidase-4 inhibitors
Randomized controlled trials
TNF-alpha
Type 2 diabetes mellitus
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
received:
31
03
2024
accepted:
27
06
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
12
7
2024
Statut:
epublish
Résumé
Dipeptidyl peptidase-4 inhibitors (DPP-4i) served as oral antidiabetic agents for treatment of type 2 diabetes mellitus (T2DM). Although an action on glucose homeostasis was identified, no well-rounded illustration had been established on the changes of tumor necrosis factor alpha (TNF-alpha) levels during DPP-4i treatment. This study aimed to explore the anti-inflammatory effect of DPP-4i on TNF-alpha in patients with T2DM. PubMed, Embase and Cochrane Library were systematically searched from inception to May 31, 2024. Randomized controlled trials exploring the impact of DPP-4i on TNF-alpha levels were identified. Risk of bias was assessed according to the Cochrane criteria. A fixed or random-effects model was selected to pool estimate on whether the heterogeneity was present. Subgroup analysis were performed to explore the potential factors that influenced heterogeneity. Related meta-analysis was conducted with the software of Revman 5.3 and STATA 12.0. Eleven trials involving 884 participants with T2DM were included. Pooled estimates suggested that DPP-4i did not significantly modulate TNF-alpha levels (WMD, - 0.70, 95% CI - 1.94 to 0.53, P = 0.26) in T2DM. DPP-4i produced a significant effect on TNF-alpha (WMD, - 4.50 pg/mL, 95% CI - 4.68 to - 4.32, P < 0.00001) when compared to placebo, and a comparable effect was demonstrated on TNF-alpha (WMD, 0.10 pg/mL, 95% CI - 0.11 to 0.30, P = 0.35) in comparison with active agents. Estimate was stable according to the sensitivity test. Subgroup analysis revealed that heterogeneity might not correlate with baseline glycated hemoglobin (HbA1c), age or treatment duration. A significant effect of DPP-4i on TNF-alpha levels was present in T2DM when compared to placebo. Administration of DPP-4i produced no significant effect on TNF-alpha in comparison with active comparators. Further studies with large samples should be performed to illustrate the impact of DPP-4i on TNF-alpha levels in T2DM. Trial registration International Prospective Register for Systematic Review (PROSPERO) number: CRD42020185479.
Identifiants
pubmed: 38997754
doi: 10.1186/s40001-024-01955-9
pii: 10.1186/s40001-024-01955-9
doi:
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Tumor Necrosis Factor-alpha
0
Hypoglycemic Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
363Informations de copyright
© 2024. The Author(s).
Références
Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S. Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four UK prospective cohort studies. Diabetes Care. 2012;35(2):396–403.
pubmed: 22210562
pmcid: 3263864
doi: 10.2337/dc11-1588
Goldfine AB, Shoelson SE. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Investig. 2017;127(1):83–93.
pubmed: 28045401
pmcid: 5199685
doi: 10.1172/JCI88884
Aljada A, Friedman J, Ghanim H, Mohanty P, Hofmeyer D, Chaudhuri A, Dandona P. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metab Clin Exp. 2006;55(9):1177–85.
pubmed: 16919536
doi: 10.1016/j.metabol.2006.04.016
Mirza RE, Fang MM, Weinheimer-Haus EM, Ennis WJ, Koh TJ. Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice. Diabetes. 2014;63(3):1103–14.
pubmed: 24194505
pmcid: 3931398
doi: 10.2337/db13-0927
Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018;14(6):491–509.
pubmed: 30409037
doi: 10.2217/fca-2018-0045
Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther. 2010;12(6):491–501.
pubmed: 20470234
doi: 10.1089/dia.2009.0172
Lamos EM, Hedrington M, Davis SN. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opin Drug Saf. 2019;18(8):691–701.
pubmed: 31150300
doi: 10.1080/14740338.2019.1626823
Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol. 2019;10:389.
doi: 10.3389/fendo.2019.00389
Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333–47.
pubmed: 26597596
doi: 10.1111/dom.12610
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.
pubmed: 33782057
pmcid: 8005924
doi: 10.1136/bmj.n71
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.
pubmed: 21195583
doi: 10.1016/j.jclinepi.2010.04.026
Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35(10):2076–82.
pubmed: 22688551
pmcid: 3447848
doi: 10.2337/dc12-0199
Jaganathan R, Ravindran R, Dhanasekaran S. Emerging role of adipocytokines in type 2 diabetes as mediators of insulin resistance and cardiovascular disease. Can J Diabetes. 2018;42(4):446-456.e441.
pubmed: 29229313
doi: 10.1016/j.jcjd.2017.10.040
Alzamil H. Elevated serum TNF-α is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance. J Obes. 2020;2020:5076858.
pubmed: 32089876
pmcid: 7013317
doi: 10.1155/2020/5076858
Kothari N, Bogra J, Abbas H, Kohli M, Malik A, Kothari D, Srivastava S, Singh PK. Tumor necrosis factor gene polymorphism results in high TNF level in sepsis and septic shock. Cytokine. 2013;61(2):676–81.
pubmed: 23317877
doi: 10.1016/j.cyto.2012.11.016
Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol. 2019;234(6):8152–61.
pubmed: 30317615
doi: 10.1002/jcp.27603
Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem. 2018;119(1):105–10.
pubmed: 28569437
doi: 10.1002/jcb.26174
Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, Sattar N. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1806–12.
pubmed: 26613768
doi: 10.1136/annrheumdis-2015-207872
Carvalho FMC, Lima VCO, Costa IS, Luz ABS, Ladd FVL, Serquiz AC, Bortolin RH, Silbiger VN, Maciel BLL, Santos EA, et al. Anti-TNF-α agent tamarind Kunitz trypsin inhibitor improves lipid profile of Wistar rats presenting dyslipidemia and diet-induced obesity regardless of PPAR-γ induction. Nutrients. 2019;11(3):512.
pubmed: 30818882
pmcid: 6470745
doi: 10.3390/nu11030512
Grossman A, Grossman E. Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol. 2017;16(1):3.
pubmed: 28056987
pmcid: 5217560
doi: 10.1186/s12933-016-0485-3
Birnbaum Y, Bajaj M, Yang HC, Ye Y. Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes. Cardiovasc Drugs Ther. 2018;32(2):135–45.
pubmed: 29508169
doi: 10.1007/s10557-018-6778-x
Wronkowitz N, Romacho T, Villalobos LA, Sell H, Eckel J. Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochem Biophys Acta. 2014;1842(9):1613–21.
pubmed: 24928308
Ghorpade DS, Ozcan L, Zheng Z, Nicoloro SM, Shen Y, Chen E, Blüher M, Czech MP, Tabas I. Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature. 2018;555(7698):673–7.
pubmed: 29562231
pmcid: 6021131
doi: 10.1038/nature26138
Birnbaum Y, Bajaj M, Qian J, Ye Y. Dipeptidyl peptidase-4 inhibition by saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ Open Diabetes Res Care. 2016;4(1): e000227.
pubmed: 27547413
pmcid: 4985834
doi: 10.1136/bmjdrc-2016-000227
Iwakura T, Zhao Z, Marschner JA, Devarapu SK, Yasuda H, Anders HJ. Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration. Nephrol Dial Transplant. 2019;34(10):1669–80.
pubmed: 30624740
doi: 10.1093/ndt/gfy397
Hwang HJ, Chung HS, Jung TW, Ryu JY, Hong HC, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS. The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms. Mol Cell Endocrinol. 2015;405(1):25–34.
pubmed: 25661535
doi: 10.1016/j.mce.2015.01.025
Esposito G, Cappetta D, Russo R, Rivellino A, Ciuffreda LP, Roviezzo F, Piegari E, Berrino L, Rossi F, De Angelis A, et al. Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. Br J Pharmacol. 2017;174(22):4070–86.
pubmed: 27922176
pmcid: 5659996
doi: 10.1111/bph.13686
Zhou X, Wang W, Wang C, Zheng C, Xu X, Ni X, Hu S, Cai B, Sun L, Shi K, et al. DPP4 inhibitor attenuates severe acute pancreatitis-associated intestinal inflammation via Nrf2 signaling. Oxid Med Cell Longev. 2019;2019:6181754.
pubmed: 31827684
pmcid: 6885240
doi: 10.1155/2019/6181754
Mokgalaboni K, Mashaba GR, Phoswa WN, Lebelo SL. Folic acid supplementation on inflammation and homocysteine in type 2 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Nutr Diabetes. 2024;14(1):22.
pubmed: 38649347
pmcid: 11035602
doi: 10.1038/s41387-024-00282-6
Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ. Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol. 2018;6(10):821–32.
pubmed: 29501322
doi: 10.1016/S2213-8587(18)30025-1
Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8–16.
pubmed: 30794833
doi: 10.1016/j.diabres.2019.02.014
Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T. Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists. Int J Mol Sci. 2021;22(19):10822.
pubmed: 34639160
pmcid: 8509708
doi: 10.3390/ijms221910822
Maiorino MI, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K, Giugliano D. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovasc Diabetol. 2021;20(1):210.
pubmed: 34663316
pmcid: 8522255
doi: 10.1186/s12933-021-01401-8
Liu X, Peng M, Wang Y, Zhai S, Liu G. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Lipids Health Dis. 2016;15(1):204.
pubmed: 27881129
pmcid: 5120528
doi: 10.1186/s12944-016-0372-7
Liu X, Men P, Wang B, Cai G, Zhao Z. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis. Lipids Health Dis. 2019;18(1):144.
pubmed: 31208420
pmcid: 6580696
doi: 10.1186/s12944-019-1086-4
Bonacina F, Baragetti A, Catapano AL, Norata GD. The interconnection between immuno-metabolism, diabetes, and CKD. Curr DiabRep. 2019;19(5):21.
Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K, Shimatsu A. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metab Clin Exp. 2013;62(3):347–51.
pubmed: 23062489
doi: 10.1016/j.metabol.2012.09.004
Tian M, Liang Z, Liu R, Li K, Tan X, Luo Y, Yang M, Gu HF, Liu H, Li L, et al. Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial. Eur J Endocrinol. 2016;174(2):147–55.
pubmed: 26546612
doi: 10.1530/EJE-15-0637
Derosa G, Maffioli P, Salvadeo S, Ferrari I, Ragonesi P, Querci F, Franzetti I, Gadaleta G, Ciccarelli L, Piccinni M, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metab Clin Exp. 2010;59:887–95.
pubmed: 20015525
doi: 10.1016/j.metabol.2009.10.007
Kitao N, Miyoshi H, Furumoto T, Ono K, Nomoto H, Miya A, Yamamoto C, Inoue A, Tsuchida K, Manda N, et al. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovasc Diabetol. 2017;16(1):125.
pubmed: 29017497
pmcid: 5634845
doi: 10.1186/s12933-017-0607-6
Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, Atsumi T, Manda N, Kurihara Y, Aoki S. A randomized controlled trial comparing the effects of sitagliptin and glimepiride on endothelial function and metabolic parameters: sapporo athero-incretin study 1 (SAIS1). PLoS ONE. 2016;11(10): e0164255.
pubmed: 27711199
pmcid: 5053511
doi: 10.1371/journal.pone.0164255
Phrommintikul A, Wongcharoen W, Kumfu S, Jaiwongkam T, Gunaparn S, Chattipakorn S, Chattipakorn N. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study. Br J Clin Pharmacol. 2019;85(6):1337–47.
pubmed: 30767253
pmcid: 6533436
doi: 10.1111/bcp.13903
Takeshita Y, Takamura T, Kita Y, Takazakura A, Kato K, Isobe Y, Kaneko S. Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study. BMJ Open Diabetes Res Care. 2015;3(1): e000122.
pubmed: 26336611
pmcid: 4553908
doi: 10.1136/bmjdrc-2015-000122
Takeshita Y, Takamura T, Kita Y, Otoda T, Kato K, Wakakuri H, Yamada M, Misu H, Matsushima Y, Kaneko S. Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: a randomized, parallel-group study. J Diabetes Investig. 2015;6(2):192–200.
pubmed: 25802727
doi: 10.1111/jdi.12269
Dei Cas A, Spigoni V, Cito M, Aldigeri R, Ridolfi V, Marchesi E, Marina M, Derlindati E, Aloe R, Bonadonna RC, et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. Cardiovasc Diabetol. 2017;16(1):27.
pubmed: 28231835
pmcid: 5324295
doi: 10.1186/s12933-017-0503-0
Takeshita Y, Kita Y, Kato KI, Kanamori T, Misu H, Kaneko S, Takamura T. Effects of metformin and alogliptin on body composition in people with type 2 diabetes. J Diabetes Investig. 2019;10(3):723–30.
pubmed: 30156056
doi: 10.1111/jdi.12920
Onoue T, Goto M, Wada E, Furukawa M, Okuji T, Okada N, Kobayashi T, Iwama S, Sugiyama M, Tsunekawa T, et al. Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: a randomized controlled trial. PLoS ONE. 2020;15(1): e0228004.
pubmed: 31990936
pmcid: 6986701
doi: 10.1371/journal.pone.0228004